According to the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA):

On May 24, 2007, three counterfeit batches of schizophrenia treatments were recalled.  Laboratory results concluded that the counterfeits only contained 60 percent of the labeled ingredient.

The following day, three lots of counterfeit blood-thinning medicine  were recalled.
In June, two more recalls occurred, one for a cancer drug and another for a blood-thinning medicine.

In all four cases, the MHRA found that the contaminated medicines were the result of the parallel trade within the European Union.

In 2007, the MHRA E&I Group launched the  UK Anti-counterfeiting Strategy which was launched in November 2007: Anti-Counterfeiting Strategy 2007 - 2010